---
document_datetime: 2025-12-02 05:45:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-teva.html
document_name: pomalidomide-teva.html
version: success
processing_time: 0.1339042
conversion_datetime: 2025-12-28 04:15:14.644913
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pomalidomide Teva

[RSS](/en/individual-human-medicine.xml/249347)

##### Authorised

This medicine is authorised for use in the European Union

pomalidomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pomalidomide Teva](#news-on)
- [Related content](#related-content-70189)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pomalidomide Teva is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is used in combination with bortezomib (another cancer medicine) and dexamethasone (an anti-inflammatory medicine) in adults who have received at least one prior treatment, including lenalidomide (another cancer medicine).

It is also used in combination with dexamethasone in adults who have received at least two prior therapies, including both lenalidomide and bortezomib, and whose disease has worsened.

Pomalidomide Teva contains the active substance pomalidomide and is a 'generic medicine'. This means that Pomalidomide Teva contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Pomalidomide Teva is Imnovid. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Pomalidomide Teva used?

Treatment with Pomalidomide Teva must be started and supervised by a doctor experienced in treating multiple myeloma. The medicine can only be obtained with a prescription.

Pomalidomide Teva is available as capsules to be taken by mouth. When given in combination with bortezomib and dexamethasone, it is taken daily in the first 2 weeks of 3-week treatment cycles. When given with dexamethasone only, it is taken daily in the first 3 weeks of 4-week treatment cycles.

If the disease gets worse or certain side effects occur, treatment with Pomalidomide Teva may need to be interrupted or stopped, or the dose may need to be reduced.

For more information about using Pomalidomide Teva, see the package leaflet or contact your doctor or pharmacist.

## How does Pomalidomide Teva work?

The active substance in Pomalidomide Teva, pomalidomide, is an immunomodulating agent. This means that it affects the activity of the immune system (the body's natural defences). In multiple myeloma, Pomalidomide works in different ways: it blocks the development of tumour cells, prevents the growth of blood vessels within tumours and stimulates some specialised cells of the immune system to attack the tumour cells.

## How has Pomalidomide Teva been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Imnovid, and do not need to be repeated for Pomalidomide Teva.

As for every medicine, the company provided studies on the quality of Pomalidomide Teva. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Pomalidomide Teva?

Because Pomalidomide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Pomalidomide Teva authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Pomalidomide Teva has been shown to have comparable quality and to be bioequivalent to Imnovid. Therefore, the Agency's view was that, as for Imnovid, the benefits of Pomalidomide Teva outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pomalidomide Teva?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pomalidomide Teva have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Imnovid, such as a patient card with key safety information, also apply to Pomalidomide Teva where appropriate.

As for all medicines, data on the use of Pomalidomide Teva are continuously monitored. Suspected side effects reported with Pomalidomide Teva are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pomalidomide Teva

Pomalidomide Teva received a marketing authorisation valid throughout the EU on 14 November 2024.

Pomalidomide Teva : EPAR - Medicine overview

Reference Number: EMA/553895/2024

English (EN) (143.84 KB - PDF)

**First published:** 28/11/2024

[View](/en/documents/overview/pomalidomide-teva-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-160)

български (BG) (164.16 KB - PDF)

**First published:**

28/11/2024

[View](/bg/documents/overview/pomalidomide-teva-epar-medicine-overview_bg.pdf)

español (ES) (142.21 KB - PDF)

**First published:**

28/11/2024

[View](/es/documents/overview/pomalidomide-teva-epar-medicine-overview_es.pdf)

čeština (CS) (161.75 KB - PDF)

**First published:**

28/11/2024

[View](/cs/documents/overview/pomalidomide-teva-epar-medicine-overview_cs.pdf)

dansk (DA) (142.06 KB - PDF)

**First published:**

28/11/2024

[View](/da/documents/overview/pomalidomide-teva-epar-medicine-overview_da.pdf)

Deutsch (DE) (146.39 KB - PDF)

**First published:**

28/11/2024

[View](/de/documents/overview/pomalidomide-teva-epar-medicine-overview_de.pdf)

eesti keel (ET) (140.03 KB - PDF)

**First published:**

28/11/2024

[View](/et/documents/overview/pomalidomide-teva-epar-medicine-overview_et.pdf)

ελληνικά (EL) (165.73 KB - PDF)

**First published:**

28/11/2024

[View](/el/documents/overview/pomalidomide-teva-epar-medicine-overview_el.pdf)

français (FR) (144.48 KB - PDF)

**First published:**

28/11/2024

[View](/fr/documents/overview/pomalidomide-teva-epar-medicine-overview_fr.pdf)

hrvatski (HR) (160.38 KB - PDF)

**First published:**

28/11/2024

[View](/hr/documents/overview/pomalidomide-teva-epar-medicine-overview_hr.pdf)

italiano (IT) (141.1 KB - PDF)

**First published:**

28/11/2024

[View](/it/documents/overview/pomalidomide-teva-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (178.64 KB - PDF)

**First published:**

28/11/2024

[View](/lv/documents/overview/pomalidomide-teva-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (161.98 KB - PDF)

**First published:**

28/11/2024

[View](/lt/documents/overview/pomalidomide-teva-epar-medicine-overview_lt.pdf)

magyar (HU) (165.48 KB - PDF)

**First published:**

28/11/2024

[View](/hu/documents/overview/pomalidomide-teva-epar-medicine-overview_hu.pdf)

Malti (MT) (165.22 KB - PDF)

**First published:**

28/11/2024

[View](/mt/documents/overview/pomalidomide-teva-epar-medicine-overview_mt.pdf)

Nederlands (NL) (143.69 KB - PDF)

**First published:**

28/11/2024

[View](/nl/documents/overview/pomalidomide-teva-epar-medicine-overview_nl.pdf)

polski (PL) (168.36 KB - PDF)

**First published:**

28/11/2024

[View](/pl/documents/overview/pomalidomide-teva-epar-medicine-overview_pl.pdf)

português (PT) (142.82 KB - PDF)

**First published:**

28/11/2024

[View](/pt/documents/overview/pomalidomide-teva-epar-medicine-overview_pt.pdf)

română (RO) (159.72 KB - PDF)

**First published:**

28/11/2024

[View](/ro/documents/overview/pomalidomide-teva-epar-medicine-overview_ro.pdf)

slovenčina (SK) (162.38 KB - PDF)

**First published:**

28/11/2024

[View](/sk/documents/overview/pomalidomide-teva-epar-medicine-overview_sk.pdf)

slovenščina (SL) (160.21 KB - PDF)

**First published:**

28/11/2024

[View](/sl/documents/overview/pomalidomide-teva-epar-medicine-overview_sl.pdf)

Suomi (FI) (140.69 KB - PDF)

**First published:**

28/11/2024

[View](/fi/documents/overview/pomalidomide-teva-epar-medicine-overview_fi.pdf)

svenska (SV) (141.31 KB - PDF)

**First published:**

28/11/2024

[View](/sv/documents/overview/pomalidomide-teva-epar-medicine-overview_sv.pdf)

Pomalidomide Teva : EPAR - Risk management plan

English (EN) (939.15 KB - PDF)

**First published:** 28/11/2024

[View](/en/documents/rmp/pomalidomide-teva-epar-risk-management-plan_en.pdf)

## Product information

Pomalidomide Teva : EPAR - Product information

English (EN) (1.23 MB - PDF)

**First published:** 28/11/2024

[View](/en/documents/product-information/pomalidomide-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-719)

български (BG) (1.69 MB - PDF)

**First published:**

28/11/2024

[View](/bg/documents/product-information/pomalidomide-teva-epar-product-information_bg.pdf)

español (ES) (1.42 MB - PDF)

**First published:**

28/11/2024

[View](/es/documents/product-information/pomalidomide-teva-epar-product-information_es.pdf)

čeština (CS) (1.67 MB - PDF)

**First published:**

28/11/2024

[View](/cs/documents/product-information/pomalidomide-teva-epar-product-information_cs.pdf)

dansk (DA) (1.36 MB - PDF)

**First published:**

28/11/2024

[View](/da/documents/product-information/pomalidomide-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.38 MB - PDF)

**First published:**

28/11/2024

[View](/de/documents/product-information/pomalidomide-teva-epar-product-information_de.pdf)

eesti keel (ET) (1.45 MB - PDF)

**First published:**

28/11/2024

[View](/et/documents/product-information/pomalidomide-teva-epar-product-information_et.pdf)

ελληνικά (EL) (1.04 MB - PDF)

**First published:**

28/11/2024

[View](/el/documents/product-information/pomalidomide-teva-epar-product-information_el.pdf)

français (FR) (1.46 MB - PDF)

**First published:**

28/11/2024

[View](/fr/documents/product-information/pomalidomide-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1.55 MB - PDF)

**First published:**

28/11/2024

[View](/hr/documents/product-information/pomalidomide-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.61 MB - PDF)

**First published:**

28/11/2024

[View](/is/documents/product-information/pomalidomide-teva-epar-product-information_is.pdf)

italiano (IT) (1.44 MB - PDF)

**First published:**

28/11/2024

[View](/it/documents/product-information/pomalidomide-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (1.69 MB - PDF)

**First published:**

28/11/2024

[View](/lv/documents/product-information/pomalidomide-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.5 MB - PDF)

**First published:**

28/11/2024

[View](/lt/documents/product-information/pomalidomide-teva-epar-product-information_lt.pdf)

magyar (HU) (1.68 MB - PDF)

**First published:**

28/11/2024

[View](/hu/documents/product-information/pomalidomide-teva-epar-product-information_hu.pdf)

Malti (MT) (1.78 MB - PDF)

**First published:**

28/11/2024

[View](/mt/documents/product-information/pomalidomide-teva-epar-product-information_mt.pdf)

Nederlands (NL) (687.39 KB - PDF)

**First published:**

28/11/2024

[View](/nl/documents/product-information/pomalidomide-teva-epar-product-information_nl.pdf)

norsk (NO) (1.64 MB - PDF)

**First published:**

28/11/2024

[View](/no/documents/product-information/pomalidomide-teva-epar-product-information_no.pdf)

polski (PL) (1.48 MB - PDF)

**First published:**

28/11/2024

[View](/pl/documents/product-information/pomalidomide-teva-epar-product-information_pl.pdf)

português (PT) (1.58 MB - PDF)

**First published:**

28/11/2024

[View](/pt/documents/product-information/pomalidomide-teva-epar-product-information_pt.pdf)

română (RO) (1.51 MB - PDF)

**First published:**

28/11/2024

[View](/ro/documents/product-information/pomalidomide-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.5 MB - PDF)

**First published:**

28/11/2024

[View](/sk/documents/product-information/pomalidomide-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.36 MB - PDF)

**First published:**

28/11/2024

[View](/sl/documents/product-information/pomalidomide-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.2 MB - PDF)

**First published:**

28/11/2024

[View](/fi/documents/product-information/pomalidomide-teva-epar-product-information_fi.pdf)

svenska (SV) (1.87 MB - PDF)

**First published:**

28/11/2024

[View](/sv/documents/product-information/pomalidomide-teva-epar-product-information_sv.pdf)

14/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pomalidomide Teva : EPAR - All authorised presentations

English (EN) (49.51 KB - PDF)

**First published:** 28/11/2024

[View](/en/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-447)

български (BG) (91.25 KB - PDF)

**First published:**

28/11/2024

[View](/bg/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (66 KB - PDF)

**First published:**

28/11/2024

[View](/es/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.79 KB - PDF)

**First published:**

28/11/2024

[View](/cs/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (53.66 KB - PDF)

**First published:**

28/11/2024

[View](/da/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (53.66 KB - PDF)

**First published:**

28/11/2024

[View](/de/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (56.85 KB - PDF)

**First published:**

28/11/2024

[View](/et/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (90.36 KB - PDF)

**First published:**

28/11/2024

[View](/el/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (61.15 KB - PDF)

**First published:**

28/11/2024

[View](/fr/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (74.49 KB - PDF)

**First published:**

28/11/2024

[View](/hr/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (57.11 KB - PDF)

**First published:**

28/11/2024

[View](/is/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (53.17 KB - PDF)

**First published:**

28/11/2024

[View](/it/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (82.3 KB - PDF)

**First published:**

28/11/2024

[View](/lv/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (90.82 KB - PDF)

**First published:**

28/11/2024

[View](/lt/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (81 KB - PDF)

**First published:**

28/11/2024

[View](/hu/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.54 KB - PDF)

**First published:**

28/11/2024

[View](/mt/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.83 KB - PDF)

**First published:**

28/11/2024

[View](/nl/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.34 KB - PDF)

**First published:**

28/11/2024

[View](/no/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (75.18 KB - PDF)

**First published:**

28/11/2024

[View](/pl/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (38.31 KB - PDF)

**First published:**

28/11/2024

[View](/pt/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (86.74 KB - PDF)

**First published:**

28/11/2024

[View](/ro/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (64.25 KB - PDF)

**First published:**

28/11/2024

[View](/sk/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (61.56 KB - PDF)

**First published:**

28/11/2024

[View](/sl/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (53.37 KB - PDF)

**First published:**

28/11/2024

[View](/fi/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.08 KB - PDF)

**First published:**

28/11/2024

[View](/sv/documents/all-authorised-presentations/pomalidomide-teva-epar-all-authorised-presentations_sv.pdf)

Pomalidomide Teva : EPAR - Conditions imposed on member states for safe and effective use - Annex related to Art. 127a

English (EN) (63.19 KB - PDF)

**First published:** 28/11/2024

[View](/en/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_en.pdf)

[Other languages (25)](#file-language-dropdown-1)

български (BG) (98.58 KB - PDF)

**First published:**

28/11/2024

[View](/bg/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_bg.pdf)

español (ES) (48.48 KB - PDF)

**First published:**

28/11/2024

[View](/es/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_es.pdf)

čeština (CS) (88.32 KB - PDF)

**First published:**

28/11/2024

[View](/cs/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_cs.pdf)

dansk (DA) (54.14 KB - PDF)

**First published:**

28/11/2024

[View](/da/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_da.pdf)

Deutsch (DE) (57.79 KB - PDF)

**First published:**

28/11/2024

[View](/de/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_de.pdf)

eesti keel (ET) (47.8 KB - PDF)

**First published:**

28/11/2024

[View](/et/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_et.pdf)

ελληνικά (EL) (101.29 KB - PDF)

**First published:**

28/11/2024

[View](/el/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_el.pdf)

français (FR) (48.98 KB - PDF)

**First published:**

28/11/2024

[View](/fr/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_fr.pdf)

hrvatski (HR) (76.22 KB - PDF)

**First published:**

28/11/2024

[View](/hr/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_hr.pdf)

íslenska (IS) (50.38 KB - PDF)

**First published:**

28/11/2024

[View](/is/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_is.pdf)

Gaeilge (GA) (206.82 KB - PDF)

**First published:**

28/11/2024

[View](/ga/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_ga.pdf)

italiano (IT) (56.69 KB - PDF)

**First published:**

28/11/2024

[View](/it/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_it.pdf)

latviešu valoda (LV) (91.04 KB - PDF)

**First published:**

28/11/2024

[View](/lv/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_lv.pdf)

lietuvių kalba (LT) (87.25 KB - PDF)

**First published:**

28/11/2024

[View](/lt/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_lt.pdf)

magyar (HU) (78.09 KB - PDF)

**First published:**

28/11/2024

[View](/hu/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_hu.pdf)

Malti (MT) (98.72 KB - PDF)

**First published:**

28/11/2024

[View](/mt/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_mt.pdf)

Nederlands (NL) (44.46 KB - PDF)

**First published:**

28/11/2024

[View](/nl/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_nl.pdf)

norsk (NO) (130.6 KB - PDF)

**First published:**

28/11/2024

[View](/no/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_no.pdf)

polski (PL) (85.54 KB - PDF)

**First published:**

28/11/2024

[View](/pl/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_pl.pdf)

português (PT) (47.87 KB - PDF)

**First published:**

28/11/2024

[View](/pt/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_pt.pdf)

română (RO) (85.48 KB - PDF)

**First published:**

28/11/2024

[View](/ro/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_ro.pdf)

slovenčina (SK) (91.86 KB - PDF)

**First published:**

28/11/2024

[View](/sk/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_sk.pdf)

slovenščina (SL) (72.67 KB - PDF)

**First published:**

28/11/2024

[View](/sl/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_sl.pdf)

Suomi (FI) (54.86 KB - PDF)

**First published:**

28/11/2024

[View](/fi/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_fi.pdf)

svenska (SV) (45.19 KB - PDF)

**First published:**

28/11/2024

[View](/sv/documents/conditions-member-states/pomalidomide-teva-epar-conditions-imposed-member-states-safe-effective-use-annex-related-art-127a_sv.pdf)

## Product details

Name of medicine Pomalidomide Teva Active substance Pomalidomide International non-proprietary name (INN) or common name pomalidomide Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L04AX06

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Pomalidomide Teva in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

Pomalidomide Teva in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

## Authorisation details

EMA product number EMEA/H/C/006302

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva GmbH

Graf-Arco-Straße 3

Opinion adopted 19/09/2024 Marketing authorisation issued 14/11/2024

## Assessment history

## Initial marketing authorisation documents

Pomalidomide Teva : EPAR - Public assessment report

Adopted

Reference Number: EMA/518385/2024

English (EN) (1 MB - PDF)

**First published:** 28/11/2024

[View](/en/documents/assessment-report/pomalidomide-teva-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Pomalidomide Teva

Adopted

Reference Number: EMA/CHMP/377627/2024

English (EN) (143.49 KB - PDF)

**First published:** 20/09/2024

[View](/en/documents/smop-initial/chmp-summary-opinion-pomalidomide-teva_en.pdf)

#### News on Pomalidomide Teva

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2024) 20/09/2024

#### Related content

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 28/11/2024

## Share this page

[Back to top](#main-content)